555 Photos and videos
#mRNA developers face challenges to meet standards for #clinical applications. In our webinar, Developing Processes for Successful Clinical-Grade mRNA Manufacturing, our experts discuss the importance of process development to meet those standards. ald.bio/3ZKTwu3
5
1
626
Non-viral modalities in dealing with #genetherapy and #celltherapy are becoming a larger consideration for #therapeutics developers, as Pat Paez discusses in a presentation from #BiotechWeekBoston ald.bio/4f1Dct2
1
472
ICYMI Defining quality attributes and analytical testing procedures. Those are the next steps as mRNA-based medicines move toward #clinical development stages. Nate Spangler discusses that in his latest blog post. #mRNA ald.bio/4i0ceVN
308
Advancement and evolution. Alex Liu discusses how they are affecting the potential for #celltherapy and #genetherapy as he looks forward to continuing the journey of transformative therapies. ald.bio/3ZclA9o
228
#bipProcessUK's annual meeting starts Tuesday in Liverpool! Take the opportunity to learn about how Aldevron can assist you in your #celltherapy and #genetherapy programs at booth 30 and see what we have to offer ald.bio/4epqZOI
177
Defining quality attributes and analytical testing procedures. Those are the next steps as mRNA-based medicines move toward #clinical development stages. Nate Spangler discusses that in his latest blog post. #mRNA ald.bio/48PRKuk
120
Meet us in Liverpool for the #bipProcessUK annual meeting to learn about how Aldevron can assist you in your #celltherapy and #genetherapy programs. Visit with Stuart King and Clare Whitewoods at booth 30 and see what we have to offer ald.bio/48HJJrt
122
#Capping efficiency is one of the concerns as #mRNA becomes widely used, with several options now available that can improve that efficiency, with RNA #polymerase being a key factor for consideration ald.bio/3UvSRtj
118
An exciting agenda is coming up @mrnaconference in Boston, Nov 12-14. Meet Aldevron’s experts to discuss the latest in #mRNA and what the future holds. Don’t miss Tao Lu’s presentation on mRNA manufacturing strategies on Nov 14 #mRNA2024 ald.bio/3NKVaFm
149
ICYMI #CRISPR offers great potential in advanced therapies. In his post, A Biological Hijack, Patrick Paez discusses his whitepaper, Next-generation CRISPR Approaches, and how new CRISPR approaches can activate #DNA repair mechanisms ald.bio/3XNGWrG
101
#CRISPR offers great potential in advanced therapies. In his post, A Biological Hijack, Patrick Paez discusses his whitepaper, Next-generation CRISPR Approaches, and how new CRISPR approaches can activate #DNA repair mechanisms. ald.bio/3BwQLmA
87
ICYMI #Nonviral #gene delivery expression levels can be boosted by Nanoplasmid™ vectors. In his post, Tyler Kozisek explains why and offers 8 different reporter constructs that #therapeutic developers can test. ald.bio/47DLMfF
78
#Nonviral #gene delivery expression levels can be boosted by Nanoplasmid™ vectors. In his post, Tyler Kozisek explains why and offers 8 different reporter constructs that #therapeutic developers can test. ald.bio/3B8juOh
88
ICYMI #mRNA drug product manufacturing requires high efficiency and reducing impurities such as #dsRNA. Learn more in our #webinar, Streamlining the Path from Discovery to Patient: Simpler RNA Manufacturing #HiCap #polymerase ald.bio/4dwdU6C
80
Early in your clinical programs? Aldevron’s new small-scale cGMP service for up to 500mg of plasmid DNA deliverables helps you advance your work. Trust your pDNA partner has been providing clients with the highest quality products and services since 1998. ald.bio/4cHVPBq
94
ICYMI Impurities in #mRNA, such as #dsRNA, can lead to adverse effects in #therapeutics. Purification can be costly and time-consuming, but there is an alternative in engineered #enzymes, as Kyle Studey points out #polymerase aldevron.co/3SPXf5D
85
#mRNA drug product manufacturing requires high efficiency and reducing impurities such as #dsRNA. Learn more in our #webinar, Streamlining the Path from Discovery to Patient: Simpler RNA Manufacturing #HiCap #polymerase ald.bio/3XdxEWQ
71
Impurities in #mRNA, such as #dsRNA, can lead to adverse effects in #therapeutics. Purification can be costly and time-consuming, but there is an alternative in engineered #enzymes, as Kyle Studey points out #polymerase aldevron.co/46NMfeF
83
ICYMI Making manufacturing process decisions early in a therapeutic’s discovery stage can be a critical factor to success, as Emilija Robinson discusses in her blog post, Had I Known Then What I Know Now #atmp #therapeutics aldevron.co/3WMUnrB
62
Making manufacturing process decisions early in a therapeutic’s discovery stage can be a critical factor to success, as Emilija Robinson discusses in her blog post, Had I Known Then What I Know Now #atmp #therapeutics aldevron.co/3WklMAA
72